Evolent Health, Inc.

NYSE:EVH

Medical - Healthcare Information Services

Healthcare
$3.93 -6.00%

-$0.28 today

Market cap
$442.05M
Beta
0.83
P/E (TTM)
-1.0
EPS (TTM)
-$4.44
52W Low $2.10High $12.07

Volume 3.10M

Average 2.78M

EVH Debt Repayment

Cash used to repay borrowings during the period.

Evolent Health, Inc.NYSE: EVH

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment outflow shrinks to $0

Q1 FY2026 debt repayment was $0, compared with $158.5M a year earlier. Trailing-twelve-month debt repayment was -$93.44M. Over 3 fiscal years it compounded at -33.3% a year.

Context

  • Debt repayment amounted to 3.5% of revenue in FY2025, up 1.2 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$23.36M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
$65.06M+11.1% YoY
LTMMar 2026
-$93.44M-142.9% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+11.1%——
3-year CAGR-33.3%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
65.06M USD
Year-over-year change
+11.1%

Debt Repayment vs competitors

How EVH compares with its peers on the latest reported figures

  • EVH's LTM Mar 2026 debt repayment of $93.44M is the 2nd largest of the 11 companies compared; the peer median is $21.5K.
  • Its year-over-year change of -142.9% is the 5th highest of 6, against a peer median of +23.6%.
  • Debt repayment amounts to 4.9% of revenue for EVH, versus a peer median of 1.4%.
EVH Competitors Peer median
Debt Repayment for EVH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMNAMN Healthcare Services, Inc.LTM Mar 2026$250M -9.1%—7.3%
EVHEvolent Health, Inc.LTM Mar 2026$93.44M -142.9%-33.3%4.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$64.5M +229.1%—7.8%
NUTXNutex Health, Inc.LTM Mar 2026$23.69M +521.5%+51.5%2.7%
PSNLPersonalis, Inc.LTM Mar 2026$5.1M -449.8%—7.9%
REPLReplimune Group, Inc.LTM Dec 2025$701K +23.6%+31.4%—
MGTXMeiraGTx Holdings plcLTM Mar 2026$43K ——0.1%
BFLYButterfly Network, Inc.LTM Mar 2026$0 ——0.0%
HSTMHealthStream, Inc.LTM Mar 2026$0 ——0.0%
KURAKura Oncology, Inc.LTM Mar 2026$0 ——0.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding EVH) $21.5K+23.6%+41.4%1.4%

Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(37.6M)(19.16M)(113.04M)(61.62M)(579.4M)
Depreciation & Amortization60.04M67.2M123.42M125.62M122.65M
Deferred Income Tax(526K)342K(31.27M)(2.82M)(2.98M)
Stock-Based Compensation16.71M33.98M40.5M39.75M39.74M
Change in Working Capital(22.49M)(104.44M)21.89M(116.56M)(57.38M)
Accounts Receivables(24.76M)(102.98M)(164.69M)32.06M73.7M
Inventory00000
Accounts Payables7.25M13.17M(6.72M)4.25M6.64M
Other Working Capital(4.98M)(14.63M)193.31M(152.87M)(137.73M)
Other Non-Cash Items22.62M10.53M101.09M34.4M516.23M
Operating Cash Flow38.75M(11.55M)142.58M18.77M38.84M
Capital Expenditures(24.98M)(38.36M)(28.75M)(24.89M)(34.09M)
Acquisitions (Net)14.22M5.55M870K(30.73M)(57.44M)
Purchases of Investments(3M)(5.55M)0(7.32M)(1M)
Sales of Investments500K5.55M07K986K
Other Investing Activities(2.53M)(226.31M)(387.67M)091.31M
Investing Cash Flow(15.79M)(259.12M)(415.54M)(62.93M)(233K)
Debt Repayment(37.69M)219.74M183.29M58.58M65.06M
Common Stock Issued13.29M4.45M180.52M3.46M0
Common Stock Repurchased0000(40M)
Dividends Paid(1.3M)(14.88M)(18.79M)(20.09M)(11.13M)
Other Financing Activities(3.85M)(77.77M)(63.68M)(42.52M)(49.86M)
Financing Cash Flow(29.55M)131.54M281.34M(565K)(35.92M)
Effect of Forex Changes(52K)(657K)(79K)(229K)11.81M
Net Change in Cash(6.64M)(139.78M)8.3M(44.96M)14.49M
Free Cash Flow13.76M(49.91M)113.84M(6.13M)4.76M

Evolent Health, Inc.

NYSE:EVH

Intrinsic Alpha fair value

Locked

Current Price

$3.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.